NEW YORK – Thermo Fisher Scientific said on Thursday that it is teaming up with NanoPin Technologies to develop liquid chromatography mass spectrometry (LC-MS) workflows for blood-based infectious disease detection.
Separately, Thermo Fisher said on Wednesday that it is partnering with Q-linea to commercialize the Swedish firm's automated antibiotic susceptibility testing instrument ASTar.
Under the collaboration with NanoPin, the firms plan to use NanoPin's diagnostic platform and Thermo Fisher's LC-MS technology to develop sensitive and fast clinical infectious disease assays to determine infection stage and monitor patient response to treatment.
"Through our agreement with Thermo Fisher, our unique diagnostic platform has the potential to change how infectious diseases, such as tuberculosis, are detected, treated, and controlled […]," said NanoPin CEO Thomas Tombler in a statement.
NanoPin, founded in 2017 and based in New Orleans, has developed technology based on antibody-conjugated nanoparticles that bind to antigen peptides only present in blood when the targeted disease is active. According to the firm's website, the technology has been proven to work for tuberculosis and HIV detection.
Under the agreement with Q-linea, Thermo Fisher has exclusive rights to offer the ASTar instrument in all geographies except Sweden. The firms plan to work closely together to provide customers with a comprehensive antibiotic susceptibility testing portfolio.
Thermo Fisher already offers the Sensititre Complete Automated AST System for determining minimal inhibitory concentration (MIC) and said its partnership with Q-linea has the potential to improve and speed up the diagnosis of patients with severe infectious diseases.
"Our distribution agreement for the Q-linea ASTar technology will enable our customers to streamline their workflow," said Christophe Fraudeau, Thermo Fisher's president of microbiology, in a statement.
Financial terms of the deals were not disclosed.